SCHEMBL1099558

SCHEMBL1099558

Cc1c(N(CCCCC(F)(F)F)S(=O)(=O)c2nc3ccccc3[nH]2)sc2ccccc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 5/20 0.37
L3MBTL1 Q9Y468 1/20 0.35
TLR8 Q9NR97 1/20 0.34
TLR7 Q9NYK1 1/20 0.34
ALDH1A1 P00352 4/20 0.32
TP53 P04637 2/20 0.32
KMT2A Q03164 3/20 0.32
CYP1A2 P05177 3/20 0.32
CYP3A4 P08684 3/20 0.32
CYP2C9 P11712 3/20 0.32
CYP2C19 P33261 3/20 0.32
MAPT P10636 3/20 0.32
CYP2D6 P10635 3/20 0.32
WDR5 P61964 2/20 0.32
ENGASE Q8NFI3 2/20 0.32
HPGD P15428 2/20 0.32
SARM1 Q6SZW1 2/20 0.32
GAA P10253 2/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1098382 0.83 L3MBTL1 (0.36) TRPM8L3MBTL1ALDH1A1TP53KMT2A
SCHEMBL1098856 0.80 TRPM8 (0.51) TRPM8
SCHEMBL1098662 0.79 TRPM8 (0.62) TRPM8
SCHEMBL1099514 0.78 TRPM8 (0.41) TRPM8TP53LMNA
SCHEMBL1099797 0.78 TRPM8 (0.63) TRPM8CNR1
SCHEMBL1099622 0.78 TRPM8 (0.37) TRPM8TLR8TLR7ALDH1A1HPGD
SCHEMBL1099774 0.77 TRPM8 (0.52) TRPM8
SCHEMBL1100065 0.77 TRPM8 (0.41) TRPM8
SCHEMBL1100541 0.76 TRPM8 (0.47) TRPM8MAPTLMNATDP1
SCHEMBL1099337 0.76 TRPM8 (0.37) TRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885L3MBTL1 3261/4885TLR8 161/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885L3MBTL1 3261/4885TLR8 161/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885L3MBTL1 3261/4885TLR8 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.